Sign In
Buy BXRX
$0.0218
+0 (+0%)
At Close: May 28, 2024
Baudax Bio Announces Corporate Update
08:00am, Wednesday, 18'th Oct 2023
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag
10:31am, Monday, 02'nd Oct 2023
FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
01:07pm, Thursday, 28'th Sep 2023
As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ: BXRX ) represented a dramatic winner. Earlier Thursday morning, management
Baudax Bio shares rocket as lead clinical candidate gains FDA orphan drug designation
12:27pm, Thursday, 28'th Sep 2023
Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug status by the United States Food and Drug Administrati
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
08:00am, Thursday, 28'th Sep 2023
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) ther
Here's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock Now
11:17am, Monday, 18'th Sep 2023
Baudax Bio, Inc. (BXRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement amo
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
08:00am, Thursday, 07'th Sep 2023
MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) ther
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
08:00am, Wednesday, 23'rd Aug 2023
MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) thera
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
08:00am, Thursday, 17'th Aug 2023
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizi
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
08:00am, Wednesday, 16'th Aug 2023
Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modes
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune
12:57pm, Monday, 03'rd Jul 2023
Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune diseases.
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
02:01pm, Friday, 30'th Jun 2023
Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight, skyrocketing into triple-digit percentage gains.
Baudax Bio shares jump on acquisition of TeraImmune
08:18am, Friday, 30'th Jun 2023
Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
10:22am, Thursday, 08'th Jun 2023
New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.
Baudax Bio Announces Date of Reconvened Annual Meeting
09:00am, Tuesday, 06'th Jun 2023
MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recentl
